RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The user tried various hair loss treatments, including Maxogen-X, Dualgen15, minoxidil, finasteride, and dermarolling, but experienced limited regrowth and some side effects. They eventually switched to oral minoxidil, hoping for better results.
Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
Genetics primarily determine hair loss, not lifestyle factors like diet, exercise, or habits. Treatments like finasteride and minoxidil are recommended, but ultimately, happiness should not depend on hair.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
User fought hair loss with Derminator microneedling, topical and oral minoxidil, and a 2000 FUE hair transplant. Derminator was a game changer, preventing further loss.
The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.